A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Umecrine Cognition AB
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female subjects age ≥ 18 years
Diagnosis of PBC based on the presence of ≥2 of 3 key disease characteristics
Clinically significant fatigue defined for the purposes of this study as a PBC-40 fatigue domain score of ≥29 at screening
Clinically significant cognitive symptoms, defined for the purposes of this study as a PBC-40 cognitive domain ≥16 at screening
Stable PBC SoC therapy (if any),for at least 3 months prior to randomisation
For all women of childbearing potential (WOCBP) a negative pregnancy test at screening and a negative urine dip-stick pregnancy test at baseline, prior to first dose of IMP
WOCBP must be willing to use a contraceptive method with a failure rate of \< 1% and agree to continue use of this method for the duration of the study and thereafter for 1 month after the last dosing of the IMP
Females of non-childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal
Fertile male subjects must be willing to use condom and assure that their female partner will use contraceptive methods with a failure rate of \< 1%
Willing and able to give informed consent
The subject should be judged by the Investigator to be lucid and oriented to person, place, time, and situation when giving the informed consent
You may not be if
Child-Pugh class B or C cirrhosis
Clinical evidence of hepatic decompensation (e.g. current or prior HE, ascites, or variceal bleeding)
Low Haemoglobin (HB), i.e. subjects with moderate/severe anaemia
Low S-B12 or low P-folate
Evidence of biliary obstruction
Any positive result on screening for human immunodeficiency virus (HIV), or hepatitis B (serum hepatitis B surface antigen positive)
Prolonged QTcF (\>500 ms), or any clinically significant abnormality in the resting ECG, as judged by the Investigator (at screening)
Concomitant disease characterised by chronic fatigue and/or cognitive impairment
Clinically significant bowel disease, including obstruction, active inflammatory bowel disease, or malabsorption
Clinically significant sleep apnoea
An uncontrolled thyroid disorder
Subjects with a history of or currently active immune disorders (i.e. uncontrolled) other that PBC (including autoimmune disease) and/or diseases requiring immunosuppressive drugs
Clinical diagnosis of autoimmune hepatitis overlap
The presence, as judged by the Investigator, of clinically significant concomitant illness which would jeopardise safe participation in the study and /or the interpretation of study findings
Regular use of prescribed or over the counter (OTC) medications known to cause fatigue or cognitive dysfunction
Use of prohibited medications within 14 days prior to randomisation
Anticipated change in PBC medication and/or significant medical or surgical intervention within the duration of the study
Regular (more than 1 week per month) alcohol consumption in excess of 14 units per week
Administration of another new chemical entity or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study
Females who are pregnant, nursing or actively trying to conceive a child
Expected inability to swallow the required number of IMP capsules at the applicable dose level
History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as judged by the Investigator